TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications

详细信息    查看全文

• 作者：Hui Liu (1) (2)
  Tiantuo Zhang (1) (2)
  Jin Ye (3)
  Hongtao Li (1) (2)
  Jing Huang (1) (2)
  Xiaodong Li (4)
  Benquan Wu (1) (2)
  Xubing Huang (2) (5)
  Jinghui Hou (6)
  
• 关键词：Apoptosis ; Chemotherapy ; Lung carcinoma ; Prognosis ; TNF receptor ; associated factor
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2012
• 出版时间：November 2012
• 年：2012
• 卷：138
• 期：11
• 页码：1853-1863
• 全文大小：528KB
• 参考文献：1. Bradley JR, Pober JS (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20(44):6482-491 CrossRef
  2. Cejas PJ, Walsh MC, Pearce EL et al (2010) TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 115(23):4750-757. doi:10.1182/blood-2009-09-242768 CrossRef
  3. Chiffoleau E, Kobayashi T, Walsh MC et al (2003) TNF receptor-associated factor 6 deficiency during hemopoiesis induces Th2-polarized inflammatory disease. J Immunol 171(11):5751-759
  4. Elmetwali T, Young LS, Palmer DH (2010) CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 184(2):1111-120. doi:10.4049/jimmunol.0900528 CrossRef
  5. Gangadharan C, Thoh M, Manna SK (2010) Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Breast Cancer Res Treat 120(3):671-83. doi:10.1007/s10549-009-0493-z CrossRef
  6. Gibbs A, Thunnissen F (2001) Histological typing of lung and pleural tumours: third edition. J Clin Pathol 54(7):498-99. doi:10.1136/jcp.54.7.498 CrossRef
  7. He L, Wu X, Siegel R, Lipsky PE (2006) TRAF6 regulates cell fate decisions by inducing caspase 8-dependent apoptosis and the activation of NF-kappaB. J Biol Chem 281(16):11235-1249. doi:10.1074/jbc.M508779200 CrossRef
  8. Hirata Y, Ohmae T, Shibata W et al (2006) MyD88 and TNF receptor-associated factor 6 are critical signal transducers in / Helicobacter pylori-infected human epithelial cells. J Immunol 176(6):3796-803
  9. Jundi M, Nadiri A, Al-Zoobi L, Hassan GS, Mourad W (2012) CD40-mediated cell death requires TRAF6 recruitment. Immunobiology 217(3):375-83. doi:10.1016/j.imbio.2011.07.007 CrossRef
  10. King CG, Kobayashi T, Cejas PJ et al (2006) TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12(9):1088-092. doi:10.1038/nm1449 CrossRef
  11. Kobayashi T, Walsh PT, Walsh MC et al (2003) TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19(3):353-63. doi:10.1016/S1074-7613(03)00230-9 CrossRef
  12. Kobayashi T, Walsh MC, Choi Y (2004) The role of TRAF6 in signal transduction and the immune response. Microbes Infect 6(14):1333-338. doi:10.1016/j.micinf.2004.09.001 CrossRef
  13. Lee NK, Lee SY (2002) Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol 35(1):61-6 CrossRef
  14. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805(2):167-80. doi:10.1016/j.bbcan.2010.01.002
  15. Liu H, Zhang T, Li X et al (2008) Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99:2185-192. doi:10.1111/j.1349-7006.2008.00922.x CrossRef
  16. Ma Y, Aymeric L, Locher C et al (2011a) Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3):491-03. doi:10.1084/jem.20100269 CrossRef
  17. Ma T, Wang N, Su Z et al (2011b) Characterization of apoptosis and proliferation in esophageal carcinoma EC109 cells following siRNA-induced down-regulation of TRAF6. Mol Cell Biochem 352(1-):77-5. doi:10.1007/s11010-011-0741-5 CrossRef
  18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-14 CrossRef
  19. Paik JH, Jang JY, Jeon YK et al (2011) MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 17(14):4761-771. doi:10.1158/1078-0432.CCR-11-0494 CrossRef
  20. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27(2):334-48. doi:10.1016/j.immuni.2007.05.020 CrossRef
  21. Rajandram R, Bennett NC, Morais C, Johnson DW, Gobe GC (2012) Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Med Hypotheses 78(2):330-36. doi:10.1016/j.mehy.2011.11.014 CrossRef
  22. Rowland SL, Tremblay MM, Ellison JM, Stunz LL, Bishop GA, Hostager BS (2007) A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol 179(7):4645-653
  23. Santarpia M, Magri I, Sanchez-Ronco M et al (2011) mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. J Transl Med 9:163. doi:10.1186/1479-5876-9-163 CrossRef
  24. Shimo Y, Yanai H, Ohshima D et al (2011) TRAF6 directs commitment to regulatory T cells in thymocytes. Genes Cells 16(4):437-47. doi:10.1111/j.1365-2443.2011.01500.x CrossRef
  25. Siervo-Sassi RR, Marrangoni AM, Feng X et al (2003) Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190(1):61-2. doi:10.1016/S0304-3835(02)00579-7 CrossRef
  26. Starczynowski DT, Lockwood WW, Deléhouzée S et al (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-kB pathways in human lung cancer. J Clin Invest 121(10):4095-105. doi:10.1172/JCI58818 CrossRef
  27. Starska K, Forma E, Lewy-Trenda I et al (2009) The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma. Folia Histochem Cytobiol 47(3):401-10. doi:10.2478/v10042-009-0075-2 CrossRef
  28. Trauzold A, R?der C, Sipos B et al (2005) CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 19(6):620-22. doi:10.1096/fj.04-2984fje
  29. Zapata JM, Krajewska M, Krajewski S et al (2000) TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 165(9):5084-096
  30. Zapata JM, Lefebvre S, Reed JC (2007) Targeting TRAfs for therapeutic intervention. Adv Exp Med Biol 597:188-01. doi:10.1007/978-0-387-70630-6_15 CrossRef
  31. Zheng M, Morgan-Lappe SE, Yang J et al (2008) Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 68(18):7570-578. doi:10.1158/0008-5472.CAN-08-0632 CrossRef
  
• 作者单位：Hui Liu (1) (2)
  Tiantuo Zhang (1) (2)
  Jin Ye (3)
  Hongtao Li (1) (2)
  Jing Huang (1) (2)
  Xiaodong Li (4)
  Benquan Wu (1) (2)
  Xubing Huang (2) (5)
  Jinghui Hou (6)
  
  1. Division of Pulmonary and Critical Care, Department of Internal Medicine, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe street, Guangzhou, 510630, China
  2. Institute of Respiratory Diseases of Sun Yat-sen University, Guangzhou, China
  3. Department of Otolaryngology—Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe street, Guangzhou, 510630, China
  4. Department of Thoracic Surgery, Cancer Center, Sun Yat-Sen University, 651 Dongfeng dong street, Guangzhou, 510060, China
  5. Division of Pulmonary and Critical Care, Department of Internal Medicine, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan Er street, Guangzhou, 510080, China
  6. Department of Pathology, Cancer Center, Sun Yat-Sen University, No. 651 Dongfeng dong street, Guangzhou, 510630, China
  
• ISSN：1432-1335

文摘

Purpose Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) represents a central point of convergence for the signal transduction by the TNFR and the IL-lR/TLR superfamilies. We conducted this retrospective clinical study focusing on TRAF6 expression associated with overall survival and chemotherapeutical sensitivity in a large population with advanced non-small cell lung cancer (NSCLC). Methods A total of 324 patients with stage III and IV NSCLC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the expression of TRAF6, apoptosis-related proteins Bcl-2, Bax, Fas, and FasL, as well as the density of CD8+ and FOXP3+ tumor infiltrating lymphocytes (TILs) in tumor microenvironment. Results A total of 193 carcinomas (59.6?%) were identified as high expression of TRAF6. TRAF6 expression was not significantly related with histology and clinic stage. No obvious correlation of TRAF6 expression with apoptosis-related protein and TILs density was identified. TRAF6 status was correlated inversely with response to chemotherapy in overall patients (response rates 24.9 and 32.8?%, for patients with high-TRAF6 and low-TRAF6 tumors, respectively, P?=?0.039). However, multivariate logistic regression analysis could not identify TRAF6 status as an independent predictor for the response to chemotherapy in overall cohort (95?% CI: 0.91-.32, P?=?0.065). The overall survival was not significantly associated with TRAF6 expression (P?=?0.616). Conclusions Our results provide new insight for the biological properties and clinical relevance of the TRAF6 in NSCLC. TRAF6 is a promise target for therapeutic strategies against cancer.